Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases
作者： Gary Clifford , Silvia Franceschi , Mireia Diaz , Nubia Muñoz , Luisa Lina Villa
DOI: 10.1016/J.VACCINE.2006.05.026
关键词:
摘要: Geographical widespread data on human papillomavirus (HPV) type-distribution are essential for estimating the impact of HPV-16/18 vaccines cervical cancer and screening programmes. Epidemiological studies employing a variety HPV typing protocols have been collated in meta-analyses. is estimated to account 70% all cancers worldwide, although fraction slightly higher more developed (72–77%) than less (65–72%) regions. About 41–67% high-grade squamous intraepithelial lesion (HSIL), 16–32% low-grade (LSIL) 6–27% atypical cells undetermined significance (ASCUS) also be HPV-16/18-positive, thus highlighting increasing relative frequency with severity. After HPV-16/18, six most common types same world regions, namely 31, 33, 35, 45, 52 58; these an additional 20% worldwide.
elsevier.com
sci-hub.se 参考文章(24)
H. D. Strickler, J. M. Palefsky, K. V. Shah, K. Anastos, R. S. Klein, H. Minkoff, A. Duerr, L. S. Massad, D. D. Celentano, C. Hall, M. Fazzari, S. Cu-Uvin, M. Bacon, P. Schuman, A. M. Levine, A. J. Durante, S. Gange, S. Melnick, R. D. Burk, Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women Journal of the National Cancer Institute. ,vol. 95, pp. 1062- 1071 ,(2003) , 10.1093/JNCI/95.14.1062
Jan M. M. Walboomers, Marcel V. Jacobs, M. Michele Manos, F. Xavier Bosch, J. Alain Kummer, Keerti V. Shah, Peter J. F. Snijders, Julian Peto, Chris J. L. M. Meijer, Nubia Mu�oz, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology. ,vol. 189, pp. 12- 19 ,(1999) , 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
DARRON R. BROWN, DENISE LEGGE, BRAHIM QADADRI, Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted diseases clinic. Sexually Transmitted Diseases. ,vol. 29, pp. 763- 768 ,(2002) , 10.1097/00007435-200212000-00005
G M Clifford, J S Smith, M Plummer, N Muñoz, S Franceschi, Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer. ,vol. 88, pp. 63- 73 ,(2003) , 10.1038/SJ.BJC.6600688
C E Depuydt, A J Vereecken, G M Salembier, A S Vanbrabant, L A Boels, E van Herck, M Arbyn, K Segers, J J Bogers, Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. British Journal of Cancer. ,vol. 88, pp. 560- 566 ,(2003) , 10.1038/SJ.BJC.6600756
Peter JF Snijders, Adriaan JC van den Brule, Chris JLM Meijer, The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. The Journal of Pathology. ,vol. 201, pp. 1- 6 ,(2003) , 10.1002/PATH.1433
G M Clifford, J S Smith, T Aguado, S Franceschi, Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis British Journal of Cancer. ,vol. 89, pp. 101- 105 ,(2003) , 10.1038/SJ.BJC.6601024
A J Zuckerman, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Journal of Clinical Pathology. ,vol. 48, pp. 691- 691 ,(1995) , 10.1136/JCP.48.7.691-A
Diane M Harper, Eduardo L Franco, Cosette M Wheeler, Anna-Barbara Moscicki, Barbara Romanowski, Cecilia M Roteli-Martins, David Jenkins, Anne Schuind, Sue Ann Costa Clemens, Gary Dubin, None, Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial The Lancet. ,vol. 367, pp. 1247- 1255 ,(2006) , 10.1016/S0140-6736(06)68439-0
T. Iftner, L. L. Villa, Chapter 12: Human papillomavirus technologies. Journal of The National Cancer Institute Monographs. ,vol. 2003, pp. 80- 88 ,(2003) , 10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A003487